Charles River Laboratories International, Inc. Share Price
Stocks
CRL
US1598641074
Biotechnology & Medical Research
|
Real-time Estimate
Cboe BZX
12:48:54 04/11/2026 am IST
|
5-day change | 1st Jan Change | ||
| 352.94 USD | +4.25% |
|
-1.72% | +76.79% |
| Market Cap | 1.62TCr 1.44TCr 1.33TCr 1.2TCr 2.26TCr 1,53100Cr 2.32TCr 16TCr 6.37TCr 81TCr 6.07TCr 5.94TCr 2,56100Cr | P/E 2026 * |
84x | P/E 2027 * | 36.2x |
|---|---|---|---|---|---|
| Enterprise Value | 1.83TCr 1.63TCr 1.5TCr 1.36TCr 2.56TCr 1,73000Cr 2.62TCr 18TCr 7.2TCr 91TCr 6.86TCr 6.71TCr 2,89500Cr | EV / Sales 2026 * |
4.66x | EV / Sales 2027 * | 4.45x |
| Free-Float |
95.58% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| CRL | Delayed | |
CBOE
| CRL | Real-time | |
Boerse Muenchen
| RV6 | Real-time | |
Mexican S.E.
| CRL * | End-of-day quote | |
Tradegate
| RV6 | Real-time | |
Deutsche Boerse AG
| RV6 | Delayed | |
Börse Stuttgart
| RV6 | Delayed | |
Xetra
| RV6 | Delayed | |
Berne S.E.
| RV6 | End-of-day quote |
Last Transcript: Charles River Laboratories International, Inc.
| 1 day | +4.17% | ||
| 1 week | -1.07% | ||
| Current month | -1.22% | ||
| 1 month | +14.24% | ||
| 3 months | +53.77% | ||
| 6 months | +106.02% | ||
| Current year | +77.97% |
| 1 week | 337.37 | 379.63 | |
| 1 month | 288.42 | 379.63 | |
| Current year | 146.2 | 379.63 | |
| 1 year | 146.2 | 379.63 | |
| 3 years | 91.86 | 379.63 | |
| 5 years | 91.86 | 397.77 | |
| 10 years | 67.36 | 460.21 |
| Manager | Title | Age | Since |
|---|---|---|---|
Birgit Girshick
CEO | Chief Executive Officer | 56 | 05/05/2026 |
Glenn Coleman
DFI | Director of Finance/CFO | 58 | 06/04/2026 |
Namandje Bumpus
CTO | Chief Tech/Sci/R&D Officer | 45 | 12/01/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
James Foster
CHM | Chairman | 75 | 01/01/2000 |
Birgit Girshick
BRD | Director/Board Member | 56 | 05/05/2026 |
Martin MacKay
CHM | Chairman | 69 | 05/05/2026 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 05/10/26 | Exercice | Executive/Senior Manager | 2,943 | 0.0062% | ||
| 30/09/26 | Buy | Chief Financial Officer | 10 | 0.0000% | ||
| 25/08/26 | Exercice | Director | 1,00,683 | 0.2090% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +4.17% | -1.07% | +98.49% | +95.16% | 1.62TCr | ||
| -2.43% | -7.34% | +36.10% | +58.44% | 6.22TCr | ||
| +0.61% | +0.77% | +11.13% | +69.42% | 5.49TCr | ||
| +0.62% | +2.58% | +20.96% | +98.18% | 5.53TCr | ||
| +1.49% | -3.33% | +22.73% | +33.11% | 4.26TCr | ||
| -1.36% | -2.76% | +14.14% | +93.69% | 4.11TCr | ||
| +3.55% | +4.01% | +226.45% | +774.01% | 4.03TCr | ||
| +0.57% | +24.09% | +99.46% | +84.11% | 3.31TCr | ||
| -1.09% | -0.05% | +13.55% | +45.35% | 3.26TCr | ||
| -3.22% | +11.14% | -43.33% | +324.69% | 2.4TCr | ||
| Average | +0.30% | +2.85% | +49.97% | +167.62% | 4.02TCr | |
| Weighted average by Cap. | +0.12% | +1.82% | +47.20% | +156.46% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 391.7Cr 349.95Cr 321.45Cr 291.94Cr 548.24Cr 37TCr 562.01Cr 3.84TCr 1.54TCr 20TCr 1.47TCr 1.44TCr 62TCr | 401.61Cr 358.8Cr 329.58Cr 299.33Cr 562.11Cr 38TCr 576.23Cr 3.93TCr 1.58TCr 20TCr 1.51TCr 1.48TCr 64TCr |
| Net income | 19Cr 17Cr 15Cr 14Cr 26Cr 1.77TCr 27Cr 183.2Cr 74Cr 935.04Cr 70Cr 69Cr 2.96TCr | 44Cr 39Cr 36Cr 33Cr 61Cr 4.14TCr 63Cr 427.87Cr 172.12Cr 2.18TCr 163.95Cr 160.44Cr 6.92TCr |
| Net Debt | 210.47Cr 188.03Cr 172.72Cr 156.86Cr 294.58Cr 20TCr 301.98Cr 2.06TCr 829.36Cr 11TCr 789.99Cr 773.09Cr 33TCr | 172.46Cr 154.08Cr 141.53Cr 128.54Cr 241.39Cr 16TCr 247.45Cr 1.69TCr 679.61Cr 8.62TCr 647.35Cr 633.5Cr 27TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 04/26/04 | $353.35 | +4.37% | 7,31,127 |
| 02/26/02 | $338.54 | -5.81% | 16,20,581 |
| 30/26/30 | $359.41 | -4.44% | 15,03,507 |
| 29/26/29 | $376.10 | +0.57% | 8,87,341 |
| 28/26/28 | $373.98 | +4.22% | 12,99,416 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.

Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CRL Stock
Select your edition
All financial news and data tailored to specific country editions

















